Perspective Therapeutics (CATX) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Upstream Bio (UPB) over the past year, losing 63.9% versus a loss of 93.8%. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $87.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | UPB |
|---|---|---|
| Share price | $0.7538 | $1.59 |
| Market cap | $91.03M | $87.15M |
| 1-day change | -3.85% | -20.50% |
| YTD return | -72.59% | -94.14% |
| 1-year return | -63.93% | -93.78% |
| 5-year return | -84.62% | — |
| EPS (TTM) | $-1.25 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-103.12M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $6.16 | $33.68 |
| 52-week low | $0.73 | $1.56 |
| Distance from 52-week high | -87.76% | -95.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1188.14% | +1245.91% |
| Average volume | 2.70M | 1.01M |
| Shares outstanding | 120.76M | 54.81M |
| Employees | 163 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed UPB by 29.8 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
CATX vs UPB FAQ
Which is bigger, Perspective Therapeutics or Upstream Bio?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $87.15M for Upstream Bio (UPB).
Which stock has performed better over the past year, CATX or UPB?
CATX returned -63.93% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.